company background image
RIGL

Rigel Pharmaceuticals NasdaqGS:RIGL Stock Report

Last Price

US$1.87

Market Cap

US$323.2m

7D

-6.5%

1Y

-22.1%

Updated

27 Jan, 2023

Data

Company Financials +

Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Stock Report

Mkt Cap: US$323.2m

RIGL Stock Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases.

RIGL fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

Rigel Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rigel Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.87
52 Week HighUS$3.52
52 Week LowUS$0.64
Beta0.74
1 Month Change42.75%
3 Month Change157.43%
1 Year Change-22.08%
3 Year Change-17.26%
5 Year Change-52.90%
Change since IPO-97.08%

Recent News & Updates

Recent updates

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06
What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14
An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 02
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year

May 12
It's Unlikely That Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Will See A Huge Pay Rise This Year

Analysts Just Published A Bright New Outlook For Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL)

Feb 22
Analysts Just Published A Bright New Outlook For Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL)

When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?

Feb 15
When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?

How Much Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Do Institutions Own?

Jan 18
How Much Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Do Institutions Own?

How Does Rigel Pharmaceuticals' (NASDAQ:RIGL) CEO Salary Compare to Peers?

Dec 21
How Does Rigel Pharmaceuticals' (NASDAQ:RIGL) CEO Salary Compare to Peers?

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 30
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Shareholder Returns

RIGLUS BiotechsUS Market
7D-6.5%0.7%2.3%
1Y-22.1%7.1%-9.7%

Return vs Industry: RIGL underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: RIGL underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is RIGL's price volatile compared to industry and market?
RIGL volatility
RIGL Average Weekly Movement15.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: RIGL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: RIGL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1996165Raul Rodriguezhttps://www.rigel.com

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase III clinical trials for the treatment of COVID-19 in hospitalized patients.

Rigel Pharmaceuticals, Inc. Fundamentals Summary

How do Rigel Pharmaceuticals's earnings and revenue compare to its market cap?
RIGL fundamental statistics
Market CapUS$323.20m
Earnings (TTM)-US$82.61m
Revenue (TTM)US$85.87m

3.8x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RIGL income statement (TTM)
RevenueUS$85.87m
Cost of RevenueUS$67.12m
Gross ProfitUS$18.75m
Other ExpensesUS$101.37m
Earnings-US$82.61m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin21.83%
Net Profit Margin-96.21%
Debt/Equity Ratio-199.9%

How did RIGL perform over the long term?

See historical performance and comparison